BioSpace News Archive

KCAS Bioanalytical and Biomarker Services, a leading bioanalytical services laboratory, is pleased to announce the expansion of leadership for the Biopharmaceutical Services team.

The Lung Cancer Research Foundation is pleased to welcome two new members of its Board of Directors, Colleen Conner Ziegler and Bruce Dunbar.

Foresight Diagnostics today announced the close of its $12.5M Series A financing led by Civilization Ventures and Bluebird Ventures, with participation by Pear Ventures, to commercialize the industry’s most sensitive minimal residual disease (MRD) detection assay.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9 at 4:40 p.m. ET.

Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization, announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 10,851,676 shares of the Company’s common stock pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission.

Viveve Medical, Inc., a medical technology company focused on women’s intimate health, announced that it has adjourned its 2021 Annual Meeting of Stockholders for a second time due to a lack of quorum.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today made an oral presentation of preclinical data from the company’s ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference.

bluebird bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 50,000 shares of common stock and 25,000 restricted stock units to its Chief Commercial Officer Tom Klima with a grant date of June 1, 2021.

Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in Europe